Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1354376

registered interest
date	09/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether members of the public who received doses of Astra Zeneca 4120Z001, 4120Z002, 4120Z003 will be entitled to receive a third dose of a vaccination recognised by the European Medicines Agency.
tabling member constituency	North Durham
tabling member printed	Mr Kevan Jones
uin	45808
answer	answer is ministerial correction date of answer 14/09/2021 answer text <p>Members of the public will not be entitled to receive a third dose of a COVID-19 vaccination on the basis of having received doses of AstraZeneca with batch numbers 4120Z001, 4120Z002, 4120Z003. All AstraZeneca vaccine doses administered in the United Kingdom are the same COVID-19 vaccine and have been authorised for use under Regulation 174, having met the strict standards on safety, quality and efficacy.</p><p>The decision to accept a particular vaccine is ultimately for individual European Union Member States. The EU has published a list of vaccines it sees as equivalent to those authorised by the European Medicines Agency for the purposes of travel includes all vaccines administered in the UK, including all batches of AstraZeneca COVID-19 vaccines.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 14/09/2021 15:34:16 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1438 label Biography information for Mr Kevan Jones

1353505

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has for a covid-19 vaccine booster campaign in autumn 2021.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	44364
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential Covid-19 booster vaccination programme on 30th June 2021, which can be found at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>The JCVI’s interim advice is that COVID-19 boosters should first be offered to the most vulnerable. The JCVI advises a two staged approach, with individuals in Stage 1 offered a COVID-19 booster vaccine, and flu vaccine, as soon as possible from September, and individuals in Stage 2 offered a COVID-19 booster vaccine as soon as practicable after Stage 1, with equal emphasis on deployment of the flu vaccine where eligible.</p><p>Final decisions on the timing and scope and cohort eligibility, including the groups listed above, of any COVID-19 vaccine booster programme will be confirmed once the JCVI have provided their final advice, alongside considerations related to COVID-19 vaccine supply and approvals by the Medicines and Healthcare products Regulatory Agency.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 13:46:11 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4385 label Biography information for Dr Philippa Whitford

1353507

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to ensure long term monitoring of immunity in people who have received different covid-19 vaccines for each dose.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	44365
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The National Institute for Health Research has commissioned the National Immunisation Schedule Evaluation Consortium to undertake the Com-CoV trial. This trial is gathering data on the long-term immune response of using different COVID-19 vaccines for the first and second dose.</p><p>Public Health England has also undertaken follow up on people given mixed schedules as part of routine care to monitor self-reported side effects and antibody response. The antibody results will be published in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 09:07:39 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4385 label Biography information for Dr Philippa Whitford

1353563

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus Certificates: British Nationals Abroad
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 July 2021 to Question 31551, when UK residents vaccinated against covid-19 while overseas with a (a) Pfizer, (b) Oxford-AstraZeneca and (c) Moderna vaccine are able to be certified as vaccinated by the UK.
tabling member constituency	North East Bedfordshire
tabling member printed	Richard Fuller
uin	44282
answer	answer is ministerial correction date of answer 13/09/2021 answer text <p>Work is underway to determine which non-Medicines and Healthcare products Regulatory Agency authorised vaccines we will recognise with confidence to enable United Kingdom residents vaccinated abroad to demonstrate their vaccination status. A solution will be rolled out in England as a pilot from the end of September.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/09/2021 16:36:09 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	3912 label Biography information for Richard Fuller

1353571

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the policy that staff at CQC-registered care homes must have received both covid-19 doses from 11 November 2021 on staffing levels in those homes.
tabling member constituency	Richmond Park
tabling member printed	Sarah Olney
uin	44423
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The Department has published an impact statement detailing the expected effect of the vaccination as a condition of deployment policy on care homes. The department will publish a full impact assessment in due course. We continue to monitor the impact of the policy on care homes as we approach 11 November.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 13:48:13 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4591 label Biography information for Sarah Olney

1353594

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the risk covid-19 poses to unvaccinated pregnant women; and what steps he is taking to ensure pregnant women receive both doses of the vaccine before their third trimester.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	44411
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>Although the overall risk from COVID-19 in pregnant women is low, in later pregnancy some women may become seriously unwell and need hospital treatment. Pregnant women with COVID-19 have a higher risk of intensive care admission than women of the same age who are not pregnant. Women with COVID-19 disease are also 2-3 times more likely to have their babies early than women without COVID-19. Pregnant women with underlying clinical conditions are at even higher risk of suffering serious complications from COVID-19.</p><p> </p><p>Currently, the Joint Committee on Vaccination and Immunisation (JCVI) recommends an interval of 8 weeks between doses of all the available COVID-19 vaccines; this includes pregnant women. It is important to note that current evidence shows that a longer dose interval produces a better immune response. The JCVI regularly reviews its advice in relation to COVID-19 Vaccination Programme, taking into account new data and evidence on the effectiveness of the programme and epidemiological situation.</p><p> </p><p>We are working hard to drive uptake in pregnant women, to ensure that as many pregnant women take up the offer of vaccination as soon as possible so that they are protected throughout their pregnancy. It is understood that pregnant women may prefer to wait to be vaccinated until after they have given birth. It is important for pregnant women to discuss their offer of vaccination with a healthcare professional in relation to the risks and benefits of the vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 13:44:02 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4510 label Biography information for Helen Hayes

1353595

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of bringing forward pregnant women's second doses of the covid-19 vaccine before their third trimester.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	44412
answer	answer is ministerial correction date of answer 13/09/2021 answer text <p>Currently, the Joint Committee on Vaccination and Immunisation (JCVI) recommends an interval of eight weeks between doses of all the available COVID-19 vaccines; this includes pregnant women. On 14 May 2021, in response to the increasing rates of infection of the Delta variant, the Government amended the interval of second doses for the most vulnerable cohorts who were offered a vaccine in phase one of the programme, from 12 weeks to an eight-week gap. The eight-week dose interval was applied to all eligible cohorts from 6 July.</p><p>It should be noted that current evidence shows that a longer dose interval produces a better immune response. As such, the JCVI has advised against reducing the dose interval further in order to maximise the effectiveness of the vaccination programme. The JCVI regularly reviews its advice in relation to COVID-19 vaccinations, taking into account new data and evidence on the effectiveness of the programme and the ongoing epidemiological situation<em>.</em></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/09/2021 10:26:14 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4510 label Biography information for Helen Hayes

1352871

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many covid-19 vaccines have been disposed of that were (a) out of date (b) unused to date.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	43653
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>The information requested is not currently centrally held. Work is ongoing across the vaccination programme to standardise and increase the information available for management purposes.</p><p>We have put in place robust mitigations throughout the vaccination programme to reduce wastage, manage expiry dates, and avoid vaccine destruction.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 11:00:27 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4658 label Biography information for Alex Sobel

1352957

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what evidence his Department holds on the potential benefits of immunisation against covid-19 for people who have previously tested positive for that virus.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	43644
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>It is not known how long antibodies made in response to natural COVID-19 infection persist, and whether immunisation could offer more protection. However, it is expected the COVID-19 vaccine would boost any pre-existing antibodies from previous infection. There is no evidence of any safety concerns from vaccinating individuals with a history of COVID-19 infection or with detectable antibodies to COVID-19. Therefore, people who have had COVID-19 disease – whether confirmed or suspected – should still receive the COVID-19 vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 09:12:09 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1353027

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the data and evidential basis which supports the decision of the Joint Committee on Vaccination and Immunisation to authorise administration of a covid-19 vaccine to people aged 16 and 17.
tabling member constituency	Gateshead
tabling member printed	Ian Mearns
uin	43491
answer	answer is ministerial correction date of answer 09/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s advice on vaccination of those aged 16 to 17 years old was published on 4 August 2021. The statement sets out the basis for the advice and includes references to supporting evidence and is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years" target="_blank">https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years</a></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 09/09/2021 16:39:03 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4000 label Biography information for Ian Mearns